CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
-Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol-
-初步數據顯示，CTX112在使用標準淋巴細胞清除方案時，具有提供有意義的臨床益處和良好的安全性特徵的潛力-
-Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for the treatment of certain relapsed or refractory (R/R) CD19-positive B-cell malignancies-
-公司宣佈，美國食品和藥物管理局（FDA）已授予CTX112再生醫學先進療法（RMAT）資格，用於治療某些複發性或難治性（R/R）CD19陽性b細胞惡性腫瘤-
-CTX112 is also in a Phase 1 clinical trial in systemic lupus erythematosus (SLE), with the potential to expand into additional autoimmune indications in the future-
-CTX112還在系統性紅斑狼瘡（SLE）的一期臨床試驗中，未來有潛力擴展到其他自身免疫適應症-
-Company expects to provide a broader update across oncology and autoimmune indications in mid-2025-
-公司預計將在2025年中期提供腫瘤學和自身免疫適應症的更廣泛更新-
ZUG, Switzerland and BOSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented data from the Company's ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and efficacy of CTX112, a next-generation CD19 allogeneic CAR T cell therapy, in relapsed or refractory (R/R) CD19-positive B-cell malignancies at the 2024 American Society of Hematology (ASH) Annual Meeting. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for the treatment of R/R follicular lymphoma and marginal zone lymphoma.
瑞士楚格和美國波士頓，2024年12月09日（環球新聞通訊）-- crispr therapeutics（納斯達克：CRSP），一家專注於爲嚴重疾病創造具有變革性的基因治療藥物的生物醫藥公司，今天在2024年美國血液學會（ASH）年會上展示了公司正在進行的第一/二期劑量遞增臨床試驗的數據，評估了CTX112（下一代CD19同種異體CAR T細胞治療）在復發或難治性（R/R）CD19陽性b細胞惡性腫瘤中的安全性和有效性。此外，公司還宣佈，美國食品和藥物管理局（FDA）已授予CTX112用於治療R/R濾泡淋巴瘤和邊緣區淋巴瘤的再生醫學先進療法（RMAT）資格。
"We are excited by these encouraging results on safety and efficacy for CTX112, which demonstrate the potential of an allogeneic CAR T treatment to produce complete remissions in heavily pre-treated patients," said Naimish Patel, M.D., Chief Medical Officer of CRISPR Therapeutics. "The data support a well-tolerated safety profile and the possibility to address the unmet need in this patient population with an off-the-shelf CAR T therapy. These results also support the potential treatment of certain autoimmune diseases by CTX112, and we are continuing to advance our SLE trial. We would like to extend our deepest gratitude to the patients, their families, and the investigators who have participated in our clinical trials. Their dedication and contributions are invaluable to advancing our programs and bringing us closer to potentially innovative treatments."
「我們對CTX112的安全性和有效性這些令人鼓舞的結果感到興奮，這表明同種異體CAR T治療在重度預處理患者中可能產生完全緩解的潛力，」crispr therapeutics的首席醫療官Naimish Patel萬.D.說。「這些數據支持良好耐受的安全特徵，並且有可能滿足這一患者群體對即用型CAR T治療的未被滿足的需求。這些結果還支持CTX112可能治療某些自身免疫疾病的潛力，而我們也在繼續推進我們的SLE試驗。我們想向參與我們臨床試驗的患者、他們的家人和研究人員表示最深切的感謝。他們的奉獻和貢獻對推動我們的項目和讓我們更接近潛在創新治療具有不可估量的價值。」
"We are very encouraged by the progress and early clinical data from CTX112, which could result in better outcomes for patients," said Armin Ghobadi, M.D., Professor of Medicine and Clinical Director, Center for Gene and Cellular Immunotherapy (CGCI), at Washington University School of Medicine. "CTX112 has shown dose-dependent efficacy and response rates that are comparable to the early autologous CAR T trials. These early results highlight the potential for CTX112 to emerge as an effective, off-the-shelf CAR T therapy for patients with relapsed or refractory CD19-positive B-cell malignancies."
「我們對CTX112的進展和早期臨床數據感到非常鼓舞，這可能導致患者獲得更好的結果，」華盛頓大學醫學院基因與細胞免疫治療中心（CGCI）醫學教授和臨床主任Armin Ghobadi萬.D.說。「CTX112顯示出劑量依賴性的有效性和反應率，這與早期的自體CAR T試驗相當。這些早期結果突出了CTX112作爲一種有效的即用型CAR T治療在復發或難治性CD19陽性b細胞惡性腫瘤患者中出現的潛力。」
CTX112 Trial Overview
The Phase 1/2 clinical trial is an open-label, multicenter study evaluating the safety and efficacy of CTX112 in relapsed or refractory (R/R) B-cell malignancies. Eligible disease subtypes include large B-cell lymphoma (LBCL), follicular lymphoma (FL) grade 1-3a, marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). CTX112 was infused after a standard course of lymphodepleting chemotherapy (3 days of 30 mg/m2 fludarabine and 500 mg/m2 cyclophosphamide).
CTX112試驗概覽
該1/2期臨床試驗是一項開放標籤、多中心研究，評估CTX112在復發或難治性（R/R）b細胞惡性腫瘤中的安全性和有效性。符合條件的疾病亞型包括大b細胞淋巴瘤（LBCL）、濾泡性淋巴瘤（FL）1-3a級、邊緣區淋巴瘤（MZL）以及披風細胞淋巴瘤（MCL）。CTX112在標準的淋巴細胞減少化療（3天30 mg/m2氟達拉濱和500 mg/m2環磷酰胺）後進行輸注。
Data were presented from 12 subjects treated during the dose escalation with CTX112 doses ranging from 30 x 106 (Dose Level [DL] 1) to 600 x 106 (DL4) CAR+ T cells. The study population was enriched for patients with high-risk characteristics, including: 1) primary refractory disease or early relapse to first-line therapy (75%); 2) high tumor burden (SPD > 4000 mm2, 50%); and 3) high disease prognostic index score (IPI, FLIPI, MZL-IPI ≥3) or elevated lactate dehydrogenase (75%).
數據顯示，12名受試者在劑量遞增期間接受了CTX112，劑量範圍從30 x 106（劑量水平[DL] 1）到600 x 106（DL4）CAR+ t細胞。研究人群以高風險特徵的患者爲主，包括：1）初次難治性疾病或對一線治療的早期復發（75%）；2）腫瘤負擔高（SPD > 4000 mm2，50%）；3）疾病預後指標評分高（IPI、FLIPI、MZL-IPI ≥ 3）或乳酸脫氫酶升高（75%）。
Safety
CTX112 was well tolerated across all dose levels. The adverse events of interest are shown in the table below.
安全性
CTX112在所有劑量水平上耐受良好。感興趣的不良事件在下表中展示。
- There were no reported dose limiting toxicities (DLTs) and no reported Grade ≥3 infections. All grade 3 or 4 cytopenias (i.e., neutropenia, thrombocytopenia, anemia) following lymphodepleting chemotherapy resolved to Grade 2 or better within 1 month of CTX112 infusion. There were no reported cases of Graft versus Host Disease (GvHD),
- All cases of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were Grade 1 or 2 per the American Society for Transplantation and Cellular Therapy (ASTCT) criteria. These low-grade CRS and ICANS events followed standard toxicity management protocols.
- 沒有報告劑量限制性毒性(DLTs)和三級及以上感染的案例。 所有在淋巴耗竭化療後出現的3級或4級血細胞減少症（即，中性粒細胞減少症，血小板減少症，貧血）在CTX112輸注後的一個月內都恢復到2級或更好。 沒有報告移植物抗宿主病(GvHD)的案例，
- 所有細胞因子釋放綜合徵（CRS）和免疫效應細胞相關神經毒性綜合徵（ICANS）的案例根據美國移植和細胞治療學會（ASTCT）標準均爲1級或2級。這些低級別的CRS和ICANS事件遵循標準毒性管理協議。
Table 1. Summary of Adverse Events of Interest
表1. 感興趣的不良事件總結
| Cell dose (CAR+ T cells) |
DL1 30x106 N=3 |
DL2 100x106 N=3 |
DL3 300x106 N=3 |
DL4 600x106 N=3 |
Total N=12 |
|||||
| Gr1-2 | Gr ≥3 | Gr1-2 | Gr ≥3 | Gr1-2 | Gr ≥3 | Gr1-2 | Gr ≥3 | Gr1-2 | Gr ≥3 | |
| CRS, n (%) | 1 (33) | 0 | 2 (67) | 0 | 1 (33) | 0 | 3 (100) | 0 | 7 (58) | 0 |
| ICANS, n (%) | 0 | 0 | 1 (33) | 0 | 1 (33) | 0 | 2 (67) | 0 | 4 (33) | 0 |
| Infections, n (%) | 1 (33) | 0 | 0 | 0 | 2 (67) | 0 | 2 (67) | 0 | 5 (42) | 0 |
| 電芯劑量 (CAR+ t細胞) |
DL1 30x106 N=3 |
DL2 100x106 N=3 |
DL3 300x106 N=3 |
DL4 600x106 N=3 |
總計 N=12 |
|||||
| Gr1-2 | Gr ≥3 | Gr1-2 | Gr ≥3 | Gr1-2 | Gr ≥3 | Gr1-2 | Gr ≥3 | Gr1-2 | Gr ≥3 | |
| CRS, n (%) | 1 (33) | 0 | 2 (67) | 0 | 1 (33) | 0 | 3 (100) | 0 | 7 (58) | 0 |
| ICANS, n (%) | 0 | 0 | 1 (33) | 0 | 1 (33) | 0 | 2 (67) | 0 | 4 (33) | 0 |
| 感染，n (%) | 1 (33) | 0 | 0 | 0 | 2 (67) | 0 | 2 (67) | 0 | 5 (42) | 0 |
Clinical Efficacy
CTX112 produced responses at all dose levels. Disease assessment was performed by investigator review according to the Lugano criteria.
臨床療效
CTX112在所有劑量水平上均產生了反應。根據盧甘諾標準由研究者進行疾病評估。
Table 2. Summary of Clinical Efficacy
表2。臨床療效總結
| Cell dose (CAR+ T cells) |
DL1 30x106 N=3 |
DL2 100x106 N=3 |
DL3 300x106 N=3 |
DL4 600x106 N=3 |
Total N=12 |
| Objective Response Rate (ORR), n (%) | 2 (67) | 2 (67) | 2 (67) | 2 (67) | 8 (67) |
| Complete Response Rate (CRR), n (%) | 1 (33) | 2 (67) | 1 (33) | 2 (67) | 6 (50) |
| Partial Response Rate, n (%) | 1 (33) | 0 | 1 (33) | 0 | 2 (17) |
| 電芯劑量 (CAR+ t細胞) |
DL1 30x106 N=3 |
DL2 100x106 N=3 |
DL3 300x106 N=3 |
DL4 600x106 N=3 |
總計 N=12 |
| 客觀響應率（ORR），n (%) | 2 (67) | 2 (67) | 2 (67) | 2 (67) | 8 (67) |
| 完全反應率 (CRR)，n (%) | 1 (33) | 2 (67) | 1 (33) | 2 (67) | 6 (50) |
| 部分反應率，n (%) | 1 (33) | 0 | 1 (33) | 0 | 2 (17) |
- Objective and complete responses were seen at all dose levels and in all treated NHL subtypes (i.e., FL, MZL, MCL and LBCL).
- Responses were also seen in patients with poor prognostic factors including primary refractory disease, early relapse, and high baseline tumor burden (e.g., SPD > 4000 mm2).
- Five patients (of the 12 treated) have achieved responses lasting for more than 6 months, including one patient whose 6-month response was confirmed after the data cut-off date. One patient treated at DL1 remains in complete remission over a year after initial CTX112 infusion. The clinical efficacy of CTX112 is supported by a clearly differentiated pharmacokinetic profile for an allogeneic CAR T cell therapy.
- The mean peak concentration and total exposure were significantly higher at DL3 and DL4 vs. DL1 and DL2. This dose dependence suggests the possibility of deeper and more durable responses as the trial moves from dose escalation to dose optimization.
- Comparing DL3, the addition of Regnase-1 and TGFβR2 edits results in 7-fold higher peak concentration (Cmax) and 9.7-fold higher mean area under the curve (AUC) for CTX112 relative to CTX110. Furthermore, at DL4, both Cmax and AUC are showing significantly more consistent and predictable increases. This suggests that the novel CRISPR/Cas9 potency edits are leading to higher CAR T cell expansion and functional persistence without enhanced or increased lymphodepleting chemotherapy doses.
- 在所有劑量水平和所有治療過的非霍奇金淋巴瘤亞型（即，濾泡性淋巴瘤、邊緣區淋巴瘤、曼特爾細胞淋巴瘤和大B細胞淋巴瘤）中均觀察到客觀和完全反應。
- 在預後不良因素的患者中，如原發性難治性疾病、早期復發和高起始腫瘤負擔（例如，SPD > 4000 mm²），也觀察到了反應。
- 在12名接受治療的患者中，有5名患者的反應持續超過6個月，其中一名患者在數據截止日期後確認了其6個月的反應。1名在DL1接受治療的患者在首次CTX112輸注後已完全緩解超過一年。CTX112的臨床療效得到了針對異體CAR電芯療法明顯區別的藥代動力學特徵的支持。
- 在DL3和DL4的平均峯濃度和總體暴露顯著高於DL1和DL2。這種劑量依賴性暗示在試驗從劑量遞增轉向劑量優化時，可能會出現更深層次和更持久的反應。
- 與DL3相比，增加Regnase-1和TGFβR2編輯導致CTX112的峯濃度（Cmax）提高了7倍，平均曲線下面積（AUC）提高了9.7倍。此外，在DL4中，Cmax和AUC均表現出更加一致和可預測的增加。這表明新穎的crispr therapeutics效力編輯帶來了更高的CAR電芯擴張和功能持久性，而無需增強或增加淋巴耗竭化療劑量。
These preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile. Given the inherent difficulties of manufacturing a CAR T therapy from a patient's own diseased cells, allogeneic cellular therapy approaches have greater potential to address the unmet need in this patient population. These promising findings underscore the potential of allogeneic cell therapies to offer a transformative option for patients, and we remain committed to advancing this innovative approach to address the significant unmet medical need in this area.
這些初步數據表明，CTX112有潛力提供有意義的臨床益處，並具有良好的耐受性安全性。鑑於從患者自身的病變細胞製造CAR電芯療法固有的困難，異體細胞療法在滿足該患者群體未被滿足的需求方面具有更大的潛力。這些有希望的發現強調了異體電芯療法爲患者提供變革性選擇的潛力，我們仍然致力於推進這種創新的方法，以解決該領域中顯著的未滿足醫療需求。
Regenerative Medicine Advanced Therapy (RMAT) Designation
Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicine pipeline products. A regenerative medicine therapy is eligible for RMAT designation if it is a cell therapy, therapeutic tissue engineering product, human cell and tissue product or any combination product of such therapies that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or therapy has the potential to address unmet medical needs for such disease or condition. Similar to Breakthrough Therapy designation, RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, including the ability for early interactions with FDA to discuss surrogate or intermediate endpoints, potential ways to support accelerated approval and satisfy post-approval requirements, potential priority review of the biologics license application (BLA) and other opportunities to expedite development and review.
再生醫學高級療法（RMAT） designation
根據21世紀醫療法案建立，RMAT designation是一個專門的項目，旨在加快有前途的再生醫學管線產品的藥物開發和審查流程。如果一種再生醫學療法是電芯療法、治療性組織工程產品、人類細胞和組織產品或任何組合的此類療法，旨在治療、修飾、逆轉或治癒嚴重或危及生命的疾病或控件，並且初步臨床證據表明該藥物或療法有潛力解決這些疾病或控件未滿足的醫療需求，則該療法可獲得RMAT designation。與突破療法designation類似，RMAT designation提供了FDA在有效藥物開發上的密集指導的好處，包括早期與FDA互動的能力，以討論替代或中間終點、支持加速批准和滿足批准後要求的潛在方式、對生物製品許可證申請（BLA）的優先審查潛力以及加快開發和審查的其他機會。
About CTX112
CTX112 is a next-generation, wholly-owned, allogeneic CAR T product candidate targeting Cluster of Differentiation 19, or CD19, which incorporates edits designed to evade the immune system, enhance CAR T potency and reduce CAR T exhaustion. CTX112 is being investigated in an ongoing clinical trial designed to assess safety and efficacy of the product candidate in adult patients with relapsed or refractory CD19-positive B-cell malignancies who have received at least two prior lines of therapy. In addition, CTX112 is being investigated in an ongoing clinical trial designed to assess safety and efficacy of the product candidate in adult patients with system lupus erythematosus.
關於CTX112
CTX112是一個下一代的、全資的、同種異體CAR t產品候選者，針對第19類分化簇（CD19），其編輯設計旨在避免免疫系統、增強CAR t效能並減少CAR t耗竭。CTX112正在進行一項臨床試驗，旨在評估該產品候選者在成人復發或難治CD19陽性B細胞惡性腫瘤患者中的安全性和有效性，這些患者至少接受過兩條前線療法。此外，CTX112還在進行一項臨床試驗，旨在評估該產品候選者在成人系統性紅斑狼瘡患者中的安全性和有效性。
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit .
關於CRISPR Therapeutics
自十多年前成立以來，crispr therapeutics 已經從一家推進基因編輯領域研究項目的研究階段公司，轉變爲一家在2023年慶祝首個基於crispr的療法獲得歷史性批准並在廣泛的疾病領域擁有多樣產品候選組合的公司，包括血紅蛋白病、腫瘤學、再生醫學、心血管疾病、自身免疫性疾病以及罕見病。crispr therapeutics於2018年將首個crispr/cas9基因編輯療法推進到臨床，以研究對鐮狀細胞病或輸血依賴性β地中海貧血的治療，從2023年底開始，CASGEVY（exagamglogene autotemcel [exa-cel]）已在一些國家獲得批准，用於治療符合條件的患者。獲得諾貝爾獎的crispr科學已經徹底改變了生物醫藥研究，代表了一種強大且經過臨床驗證的方法，可能創造出一類具有轉變潛力的新藥物。爲了加速和擴展其努力，crispr therapeutics已與包括拜耳和福泰製藥在內的領先公司建立了戰略合作關係。crispr therapeutics AG總部位於瑞士楚格，並擁有全資美國子公司crispr therapeutics, Inc.及位於馬薩諸塞州波士頓和加利福尼亞州舊金山的研發業務辦公室，以及位於英國倫敦的商務辦公室。要了解更多信息，請訪問。
CRISPR THERAPEUTICS standard character mark and design logo, CTX110 and CTX112 are trademarks and registered trademarks of CRISPR Therapeutics AG. The CASGEVY word mark and design are trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.
crispr therapeutics標準字符標記和設計logo，CTX110和CTX112是crispr therapeutics AG的商標和註冊商標。CASGEVY字標和設計是福泰製藥公司的商標。所有其他商標和註冊商標均爲其各自所有者的財產。
CRISPR Special Note Regarding Forward-Looking Statement
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) CRISPR Therapeutics' preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) the clinical data being presented at the 2024 ASH Annual Meeting; (iii) discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics including, without limitation, expectations regarding the benefits of RMAT designation; and (iv) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading "Risk Factors" in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release other than to the extent required by law.
關於前瞻性聲明的crispr特別說明
本新聞稿中涉及非歷史事實的陳述是1995年《私人證券訴訟改革法案》中所指的「前瞻性聲明」。由於此類聲明受風險和不確定性影響，實際結果可能與此類前瞻性聲明所表達或暗示的結果存在重大差異。此類聲明包括但不限於以下任一或所有事項的陳述：（i）crispr therapeutics的臨床前研究、臨床試驗以及產品及項目管道，包括但不限於，製造能力、此類研究和試驗的狀態、潛在擴展至新適應症的可能性以及對數據、安全性和有效性的預期；（ii）將在2024年ASH年會上展示的臨床數據；（iii）與監管機構對crispr therapeutics開發的產品候選的討論，包括但不限於對RMAt認證收益的預期；以及（iv）基因編輯技術和療法的治療價值、發展和商業潛力，包括crispr/cas9。造成前瞻性聲明不確定性的風險包括但不限於在crispr therapeutics最近的10-K表格年報和其以後的任何文件中討論的「風險因素」。現有及潛在的投資者應謹慎行事，不要對這些前瞻性聲明抱有過度依賴，這些聲明僅在其發佈日期時有效。公司不承擔更新或修訂本新聞稿中包含的任何前瞻性聲明的義務或承諾，除非法律要求。
This press release discusses CRISPR/Cas9 gene editing investigational therapies and is not intended to convey conclusions about efficacy or safety as to those investigational therapies or uses of such investigational therapies. There is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities.
本新聞稿討論CRISPR/Cas9基因編輯的調查療法，並不旨在傳達有關這些調查療法的療效或安全性結論，也不旨在傳達這些調查療法的用途。不能保證任何調查療法能夠成功完成臨床開發或獲得適用監管機構的批准。
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
投資者聯繫人：
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4167
rachel.eides@crisprtx.com
媒體聯繫：
Rachel Eides
+1-617-315-4167
rachel.eides@crisprtx.com
譯文內容由第三人軟體翻譯。